Åsa Kumlin Howell

Åsa Kumlin Howell

Auto-generated profile, based on publicly available information

Åsa Kumlin Howell

Swedish Medical Products Agency, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Drug Discovery Today
Verified
Journal Article
Open access
VSViktoriia Starokozhko
Viktoriia Starokozhko
MKMarko Kallio
Marko Kallio
ÅHÅsa Kumlin Howell
Åsa Kumlin Howell
ASAnna Mäkinen Salmi
Anna Mäkinen Salmi
GAGunilla Andrew-Nielsen
Gunilla Andrew-Nielsen
PMPeter G.M. Mol
Peter G.M. Mol
Truly disruptive medicine innovation and new treatment paradigms tend to start in non-commercial research institutions. However, the lack of mutual understanding between medicine developers and regulators when it comes to medicine development significantly delays or even prevents the access of patients to these innovations. Here, we outline what regulatory-related barriers hamper the translational development of novel products or new treatment paradigms initiated in academia, and propose key steps towards improved regulatory dialogue among academia, funding bodies and regulatory authorities. Moreover, we briefly describe how the STARS (Strengthening Training of Academia in Regulatory Science) project aims to reach out to medicine innovators in academia to bridge the regulatory knowledge gap and enhance this dialogue to facilitate the implementation of academic research findings in clinical practice.